ACCG-2671

updated

ACCG-2671 is Structure Therapeutics' investigational oral, non-peptide, small-molecule dual amylin and calcitonin receptor agonist. The only human data are single-dose results in 31 healthy adults without obesity, announced by the company on 8 September 2026 and not peer reviewed. Its structure is not disclosed, and multiple-dose data are expected in the first half of 2027.

Oral small-molecule dual amylin and calcitonin receptor agonist (DACRA)

  • Structure Therapeutics describes ACCG-2671 as an oral, non-peptide, small-molecule DACRA. No structure, INN or PubChem record is public, and an openFDA query and a DailyMed search on 10 October 2026 found no application or label.
  • The company reported on 8 September 2026 single-dose results in 31 healthy adults without obesity (1, 2, 5 or 10 mg or placebo): Tmax of 1 to 1.5 hours, dose-proportional exposure and a terminal half-life of about 6 days.
  • The company reported no serious adverse events. Gastrointestinal events appeared at 5 mg (nausea in 4 of 5, vomiting in 3 of 5) and at 10 mg (6 of 6 participants).
  • A single 10 mg dose (6 participants) was associated with a 3.3% mean body weight reduction at day 24, an exploratory company-reported finding with no placebo comparison, in participants without obesity.
  • The company's 10-K reports dose-dependent weight reductions with oral doses in diet-induced obese rats. Its heading "cagrilintide-like efficacy" is the company's rat comparison, not a human result.
  • No peer-reviewed report was found. The first-in-human study (NCT07815678, estimated 164 participants) has no posted results, and multiple-dose topline data are expected in the first half of 2027.

What is ACCG-2671, and is it approved?

ACCG-2671 is Structure Therapeutics' investigational oral, non-peptide, small-molecule dual amylin and calcitonin receptor agonist. FDA database searches on 10 October 2026 found no application or label, and its structure is not disclosed.

Structure Therapeutics' 10-K for 2025, filed 26 February 2026, says the company announced the selection of ACCG-2671 as its lead oral amylin agonist for obesity in December 2024, designed as an oral small molecule dual amylin and calcitonin receptor agonist (DACRA), and that a Phase 1 study began in December 2025. Its release of 8 September 2026 repeats the description "oral, non-peptide, small molecule" DACRA. A second candidate, ACCG-3535, is described as a different chemical structure.

PubChem returned no record for ACCG-2671 or ACCG2671 on 10 October 2026, the structure is not disclosed in the records reviewed, the sources give no INN, and the WHO proposed INN lists 126 to 135, which print no development codes, contain no entry that could be tied to ACCG-2671.

ClinicalTrials.gov lists the sponsor of the first-in-human study as "Aconcagua Bio, Inc., a wholly owned subsidiary of Structure Therapeutics". The 8 September 2026 release names ACCG-2671 and the GLP-1 agonist aleniglipron as the company's two lead product candidates, and the 10-K calls ACCG-2671 its lead oral amylin candidate.

An openFDA Drugs@FDA query for ACCG-2671 returned "No matches found" on 10 October 2026, while a control query for semaglutide returned records, and a DailyMed drug name search returned 0 labels. Status outside the United States is not covered here.

Structure Therapeutics 10-K (filed 26 February 2026): oral small-molecule DACRA

Regulatory record

Structure Therapeutics Form 10-K for 2025, filed 26 February 2026. SEC EDGAR.

The 10-K says the company announced the selection of ACCG-2671 as its lead oral amylin agonist for obesity in December 2024, designed as an oral small molecule dual amylin and calcitonin receptor agonist (DACRA), and that a Phase 1 study began in December 2025. It calls ACCG-2671 its lead oral amylin candidate. A second candidate, ACCG-3535, is described as a different chemical structure.

Participants / model
Company description, not a clinical population
Treatment
Oral small molecule
Follow-up
Filed 26 February 2026
Study design
Company filing
Funding
not stated in the source

A company description. PubChem returned no record for ACCG-2671 or ACCG2671 on 10 October 2026, and the sources give no INN; those findings come from record searches, not from this filing.

Read the original source
Company statement, 8 September 2026: 31 healthy adults, half-life about 6 days, not peer reviewed

Clinical trial

Structure Therapeutics Form 8-K exhibit dated 8 September 2026. SEC EDGAR.

31 healthy adults without obesity received a single dose of 1, 2, 5 or 10 mg or placebo. Tmax was 1 to 1.5 hours, exposure was dose proportional, and the terminal half-life was about 6 days. There were no serious adverse events, no drug-related adverse events leading to discontinuation and no events of drug-induced liver injury. No nausea or vomiting was reported on placebo, 1 mg or 2 mg. Gastrointestinal events emerged at 5 mg (nausea in 4 of 5, vomiting in 3 of 5) and at 10 mg (6 of 6 participants; the release does not say which events). Exploratory findings: a single 10 mg dose (n = 6) was associated with a mean body weight reduction of 3.3% at day 24, and the bone resorption marker CTX-1 fell by about 60% on day 2 across the active cohorts. The release names ACCG-2671 and the GLP-1 agonist aleniglipron as the company's two lead product candidates, repeats the description "oral, non-peptide, small molecule" DACRA, and says the 84-day multiple dose part has started in five cohorts of people with obesity, with topline data expected in the first half of 2027.

Participants / model
Healthy adults without obesity, 31 in the single ascending dose part
Treatment
Single oral dose, 1 to 10 mg
Follow-up
Body weight at day 24; CTX-1 on day 2
Study design
Company statement of phase 1/2a single ascending dose topline results; not peer reviewed
Funding
not stated in the source

The release gives no placebo comparison for the weight figure, and the participants did not have obesity. The 10 mg gastrointestinal events were not itemized. The release calls the program both phase 1/2a and phase 1b/2a.

Read the original source
Registry: phase 1/2 first-in-human, 164 planned, no posted results

Trial registry record

ClinicalTrials.gov. NCT07815678 (sponsor Aconcagua Bio, Inc.).

The registry lists the sponsor of the ACCG-2671 first-in-human study as "Aconcagua Bio, Inc., a wholly owned subsidiary of Structure Therapeutics". NCT07815678 is a randomized, triple-masked phase 1/2 study of safety, tolerability, pharmacokinetics and food effect, estimated 164 participants aged 25 to 75, with a listed start of 29 December 2025, primary completion in March 2027, and first posted on 11 September 2026 (after the listed start). Parts 1 and 2 enroll healthy participants, and part 3 enrolls otherwise healthy participants with obesity, with safety, vital sign, ECG and laboratory primary outcomes. The registry has no posted results.

Participants / model
Healthy adults, then adults with obesity (planned)
Treatment
Oral, single and multiple ascending doses
Follow-up
Listed start 29 December 2025; primary completion March 2027
Study design
Official trial registry
Funding
not stated in the source

A registration, not an outcome. The registry was first posted more than eight months after the listed start date.

Read the original source
FDA record search, 10 October 2026: no application or label

Regulatory record

U.S. Food and Drug Administration, openFDA Drugs@FDA query and DailyMed drug name search for ACCG-2671, run on 10 October 2026.

An openFDA Drugs@FDA query for ACCG-2671 returned "No matches found" (a control query for semaglutide returned records), and a DailyMed drug name search for ACCG-2671 returned 0 labels.

Participants / model
FDA databases, not a clinical population
Treatment
Name search
Follow-up
Queries run on 10 October 2026
Study design
Dated US approval-record search
Funding
not stated in the source

A search result shows what the databases returned on that date. It is US-scoped and does not cover approvals elsewhere.

Read the original source

What did the single-dose study find?

In a company statement of 8 September 2026, single oral doses of 1 to 10 mg in 31 healthy adults without obesity gave a Tmax of 1 to 1.5 hours and a terminal half-life of about 6 days. A 3.3% weight reduction in 6 participants at 10 mg had no placebo comparison. No peer-reviewed report exists.

On 8 September 2026, Structure Therapeutics reported topline results from the single ascending dose part of a phase 1/2a study in an exhibit to a Form 8-K. 31 healthy adults without obesity received a single oral dose of 1, 2, 5 or 10 mg or placebo. The company reported a Tmax of 1 to 1.5 hours, dose-proportional exposure and a terminal half-life of about 6 days.

The company described exploratory findings: a single 10 mg dose (n = 6) was associated with a mean body weight reduction of 3.3% at day 24, and the bone resorption marker CTX-1 fell by about 60% on day 2 across the active cohorts. The release gives no placebo comparison for the weight figure, and the participants did not have obesity.

These figures are a company statement. PubMed queries on 10 October 2026 for ACCG-2671 and ACCG2671 returned 0 records each. A free-text query for Structure Therapeutics oral small molecule amylin receptor agonist returned 2 incretin review papers whose abstracts do not mention ACCG, and an affiliation query for Structure Therapeutics with amylin or aleniglipron returned 2 records about the GLP-1 agonist aleniglipron (a phase 2b report and its correction). No peer-reviewed report of ACCG-2671 data was found.

Company statement, 8 September 2026: 31 healthy adults, half-life about 6 days, not peer reviewed

Clinical trial

Structure Therapeutics Form 8-K exhibit dated 8 September 2026. SEC EDGAR.

31 healthy adults without obesity received a single dose of 1, 2, 5 or 10 mg or placebo. Tmax was 1 to 1.5 hours, exposure was dose proportional, and the terminal half-life was about 6 days. There were no serious adverse events, no drug-related adverse events leading to discontinuation and no events of drug-induced liver injury. No nausea or vomiting was reported on placebo, 1 mg or 2 mg. Gastrointestinal events emerged at 5 mg (nausea in 4 of 5, vomiting in 3 of 5) and at 10 mg (6 of 6 participants; the release does not say which events). Exploratory findings: a single 10 mg dose (n = 6) was associated with a mean body weight reduction of 3.3% at day 24, and the bone resorption marker CTX-1 fell by about 60% on day 2 across the active cohorts. The release names ACCG-2671 and the GLP-1 agonist aleniglipron as the company's two lead product candidates, repeats the description "oral, non-peptide, small molecule" DACRA, and says the 84-day multiple dose part has started in five cohorts of people with obesity, with topline data expected in the first half of 2027.

Participants / model
Healthy adults without obesity, 31 in the single ascending dose part
Treatment
Single oral dose, 1 to 10 mg
Follow-up
Body weight at day 24; CTX-1 on day 2
Study design
Company statement of phase 1/2a single ascending dose topline results; not peer reviewed
Funding
not stated in the source

The release gives no placebo comparison for the weight figure, and the participants did not have obesity. The 10 mg gastrointestinal events were not itemized. The release calls the program both phase 1/2a and phase 1b/2a.

Read the original source
PubMed search, 10 October 2026: no record for ACCG-2671

PubMed search record

PubMed searches run on 10 October 2026 for ACCG-2671 and ACCG2671 (0 records each), a free-text query for Structure Therapeutics oral small molecule amylin receptor agonist (2 records) and an affiliation query for Structure Therapeutics with amylin or aleniglipron (2 records).

PubMed queries for ACCG-2671 and ACCG2671 returned 0 records each. A free-text query for Structure Therapeutics oral small molecule amylin receptor agonist returned 2 incretin review papers whose abstracts do not mention ACCG, and an affiliation query for Structure Therapeutics with amylin or aleniglipron returned 2 records about the GLP-1 agonist aleniglipron (a phase 2b report and its correction). No peer-reviewed report of ACCG-2671 data was found.

Participants / model
Records returned, not a population
Treatment
Not applicable
Follow-up
Searches run on 10 October 2026
Study design
Literature search
Funding
not stated in the source

A search result shows what PubMed returned on that date. It is not proof that no unindexed study exists.

Read the original source

What do the preclinical data show?

The company's 10-K reports high affinity and balanced potency at human amylin and calcitonin receptors in cell assays, and dose-dependent weight reductions with oral doses in diet-induced obese rats. These are company statements, and the heading "cagrilintide-like efficacy" is its own rat comparison, not a human result.

In the 10-K filed 26 February 2026, Structure Therapeutics reports that ACCG-2671 showed high binding affinity and balanced potency in human calcitonin receptor and amylin receptor functional assays, and sub-nanomolar potency in the company's DACRA assay. In diet-induced obese rats, oral doses produced significant dose-dependent body weight reductions, and combination with semaglutide (concurrent or as an add-on) gave more weight loss than ACCG-2671 alone. The doses are not stated in the sources reviewed.

The filing's own heading says "cagrilintide-like efficacy" in the rat model. That is the company's comparison and not a human result. No peer-reviewed preclinical paper was found.

Company statement in the 10-K: receptor potency and oral weight loss in diet-induced obese rats

Animal study

Structure Therapeutics Form 10-K for 2025, filed 26 February 2026. SEC EDGAR.

ACCG-2671 showed high binding affinity and balanced potency in human calcitonin receptor and amylin receptor functional assays, and sub-nanomolar potency in the company's DACRA assay. In diet-induced obese rats, oral doses produced significant dose-dependent body weight reductions, and combination with semaglutide (concurrent or as an add-on) gave more weight loss than ACCG-2671 alone. The filing's own heading says "cagrilintide-like efficacy" in the rat model.

Participants / model
Diet-induced obese rats and cell assays with human receptors
Treatment
Oral dosing in rats; dose not stated in the sources reviewed
Follow-up
not stated in the source
Study design
Company statement of preclinical results in a filing; no peer-reviewed paper found
Funding
not stated in the source

The "cagrilintide-like efficacy" heading is the company's own comparison in the rat model, not a human result. No peer-reviewed preclinical paper was found.

Read the original source

What is registered, and when do multiple-dose results arrive?

NCT07815678 is a randomized, triple-masked phase 1/2 first-in-human study, estimated 164 participants, registered with no posted results. The company said on 8 September 2026 that the 84-day multiple dose part has started in people with obesity, with topline data expected in the first half of 2027.

NCT07815678 (Aconcagua Bio) is a randomized, triple-masked phase 1/2 first-in-human study of safety, tolerability, pharmacokinetics and food effect, estimated 164 participants aged 25 to 75, with a listed start of 29 December 2025 and primary completion in March 2027. It was first posted on 11 September 2026, after the listed start. Parts 1 and 2 enroll healthy participants, and part 3 enrolls otherwise healthy participants with obesity, with safety, vital sign, ECG and laboratory primary outcomes. The registry has no posted results.

The 8 September 2026 release says the 84-day multiple ascending dose part has started in five cohorts of people with obesity, including daily and weekly regimens and a cohort on a stable injectable GLP-1 agonist, with topline data expected in the first half of 2027. The release calls the program both phase 1/2a and phase 1b/2a. A registration is not an outcome, and no multiple-dose result exists.

Registry: phase 1/2 first-in-human, 164 planned, no posted results

Trial registry record

ClinicalTrials.gov. NCT07815678 (sponsor Aconcagua Bio, Inc.).

The registry lists the sponsor of the ACCG-2671 first-in-human study as "Aconcagua Bio, Inc., a wholly owned subsidiary of Structure Therapeutics". NCT07815678 is a randomized, triple-masked phase 1/2 study of safety, tolerability, pharmacokinetics and food effect, estimated 164 participants aged 25 to 75, with a listed start of 29 December 2025, primary completion in March 2027, and first posted on 11 September 2026 (after the listed start). Parts 1 and 2 enroll healthy participants, and part 3 enrolls otherwise healthy participants with obesity, with safety, vital sign, ECG and laboratory primary outcomes. The registry has no posted results.

Participants / model
Healthy adults, then adults with obesity (planned)
Treatment
Oral, single and multiple ascending doses
Follow-up
Listed start 29 December 2025; primary completion March 2027
Study design
Official trial registry
Funding
not stated in the source

A registration, not an outcome. The registry was first posted more than eight months after the listed start date.

Read the original source
Company statement, 8 September 2026: 31 healthy adults, half-life about 6 days, not peer reviewed

Clinical trial

Structure Therapeutics Form 8-K exhibit dated 8 September 2026. SEC EDGAR.

31 healthy adults without obesity received a single dose of 1, 2, 5 or 10 mg or placebo. Tmax was 1 to 1.5 hours, exposure was dose proportional, and the terminal half-life was about 6 days. There were no serious adverse events, no drug-related adverse events leading to discontinuation and no events of drug-induced liver injury. No nausea or vomiting was reported on placebo, 1 mg or 2 mg. Gastrointestinal events emerged at 5 mg (nausea in 4 of 5, vomiting in 3 of 5) and at 10 mg (6 of 6 participants; the release does not say which events). Exploratory findings: a single 10 mg dose (n = 6) was associated with a mean body weight reduction of 3.3% at day 24, and the bone resorption marker CTX-1 fell by about 60% on day 2 across the active cohorts. The release names ACCG-2671 and the GLP-1 agonist aleniglipron as the company's two lead product candidates, repeats the description "oral, non-peptide, small molecule" DACRA, and says the 84-day multiple dose part has started in five cohorts of people with obesity, with topline data expected in the first half of 2027.

Participants / model
Healthy adults without obesity, 31 in the single ascending dose part
Treatment
Single oral dose, 1 to 10 mg
Follow-up
Body weight at day 24; CTX-1 on day 2
Study design
Company statement of phase 1/2a single ascending dose topline results; not peer reviewed
Funding
not stated in the source

The release gives no placebo comparison for the weight figure, and the participants did not have obesity. The 10 mg gastrointestinal events were not itemized. The release calls the program both phase 1/2a and phase 1b/2a.

Read the original source

Is ACCG-2671 an oral small-molecule amylin receptor agonist in phase 1?

Yes, with a correction. The compound, the developer and the phase 1 stage are confirmed in Structure Therapeutics' own filings, but the company calls it a dual amylin and calcitonin receptor agonist, and all human data are single-dose company figures.

The claim describes an oral small-molecule amylin receptor agonist from Structure Therapeutics, in phase 1.

The compound and developer are confirmed in the company's 10-K and its 8 September 2026 release. The amylin receptor agonist wording is right in general, but the company's own mechanism label is dual amylin and calcitonin receptor agonism.

Phase 1 is right: the single ascending dose part reported on 8 September 2026 and the multiple dose part has started. All human figures are a company statement, and the weight figure came from 6 participants without obesity and with no placebo comparison.

Structure Therapeutics 10-K (filed 26 February 2026): oral small-molecule DACRA

Regulatory record

Structure Therapeutics Form 10-K for 2025, filed 26 February 2026. SEC EDGAR.

The 10-K says the company announced the selection of ACCG-2671 as its lead oral amylin agonist for obesity in December 2024, designed as an oral small molecule dual amylin and calcitonin receptor agonist (DACRA), and that a Phase 1 study began in December 2025. It calls ACCG-2671 its lead oral amylin candidate. A second candidate, ACCG-3535, is described as a different chemical structure.

Participants / model
Company description, not a clinical population
Treatment
Oral small molecule
Follow-up
Filed 26 February 2026
Study design
Company filing
Funding
not stated in the source

A company description. PubChem returned no record for ACCG-2671 or ACCG2671 on 10 October 2026, and the sources give no INN; those findings come from record searches, not from this filing.

Read the original source
Company statement, 8 September 2026: 31 healthy adults, half-life about 6 days, not peer reviewed

Clinical trial

Structure Therapeutics Form 8-K exhibit dated 8 September 2026. SEC EDGAR.

31 healthy adults without obesity received a single dose of 1, 2, 5 or 10 mg or placebo. Tmax was 1 to 1.5 hours, exposure was dose proportional, and the terminal half-life was about 6 days. There were no serious adverse events, no drug-related adverse events leading to discontinuation and no events of drug-induced liver injury. No nausea or vomiting was reported on placebo, 1 mg or 2 mg. Gastrointestinal events emerged at 5 mg (nausea in 4 of 5, vomiting in 3 of 5) and at 10 mg (6 of 6 participants; the release does not say which events). Exploratory findings: a single 10 mg dose (n = 6) was associated with a mean body weight reduction of 3.3% at day 24, and the bone resorption marker CTX-1 fell by about 60% on day 2 across the active cohorts. The release names ACCG-2671 and the GLP-1 agonist aleniglipron as the company's two lead product candidates, repeats the description "oral, non-peptide, small molecule" DACRA, and says the 84-day multiple dose part has started in five cohorts of people with obesity, with topline data expected in the first half of 2027.

Participants / model
Healthy adults without obesity, 31 in the single ascending dose part
Treatment
Single oral dose, 1 to 10 mg
Follow-up
Body weight at day 24; CTX-1 on day 2
Study design
Company statement of phase 1/2a single ascending dose topline results; not peer reviewed
Funding
not stated in the source

The release gives no placebo comparison for the weight figure, and the participants did not have obesity. The 10 mg gastrointestinal events were not itemized. The release calls the program both phase 1/2a and phase 1b/2a.

Read the original source
Registry: phase 1/2 first-in-human, 164 planned, no posted results

Trial registry record

ClinicalTrials.gov. NCT07815678 (sponsor Aconcagua Bio, Inc.).

The registry lists the sponsor of the ACCG-2671 first-in-human study as "Aconcagua Bio, Inc., a wholly owned subsidiary of Structure Therapeutics". NCT07815678 is a randomized, triple-masked phase 1/2 study of safety, tolerability, pharmacokinetics and food effect, estimated 164 participants aged 25 to 75, with a listed start of 29 December 2025, primary completion in March 2027, and first posted on 11 September 2026 (after the listed start). Parts 1 and 2 enroll healthy participants, and part 3 enrolls otherwise healthy participants with obesity, with safety, vital sign, ECG and laboratory primary outcomes. The registry has no posted results.

Participants / model
Healthy adults, then adults with obesity (planned)
Treatment
Oral, single and multiple ascending doses
Follow-up
Listed start 29 December 2025; primary completion March 2027
Study design
Official trial registry
Funding
not stated in the source

A registration, not an outcome. The registry was first posted more than eight months after the listed start date.

Read the original source

How does ACCG-2671 work, and how long does it last in the body?

Structure Therapeutics designed ACCG-2671 as an oral small-molecule dual amylin and calcitonin receptor agonist. In the company-reported single dose study, Tmax was 1 to 1.5 hours and the terminal half-life was about 6 days.

The company's 10-K describes ACCG-2671 as designed as an oral small molecule dual amylin and calcitonin receptor agonist (DACRA), with high binding affinity and balanced potency in human calcitonin receptor and amylin receptor assays. The amylin mechanism has support from class data from injectable amylin analogs, such as the published phase 2 trial of petrelintide on its own page. No peer-reviewed human data for ACCG-2671 were found.

In the company-reported single ascending dose study, Tmax was 1 to 1.5 hours, exposure was dose proportional and the terminal half-life was about 6 days. The company also reported that the bone resorption marker CTX-1 fell by about 60% on day 2 across the active cohorts, an exploratory finding.

Structure Therapeutics 10-K (filed 26 February 2026): oral small-molecule DACRA

Regulatory record

Structure Therapeutics Form 10-K for 2025, filed 26 February 2026. SEC EDGAR.

The 10-K says the company announced the selection of ACCG-2671 as its lead oral amylin agonist for obesity in December 2024, designed as an oral small molecule dual amylin and calcitonin receptor agonist (DACRA), and that a Phase 1 study began in December 2025. It calls ACCG-2671 its lead oral amylin candidate. A second candidate, ACCG-3535, is described as a different chemical structure.

Participants / model
Company description, not a clinical population
Treatment
Oral small molecule
Follow-up
Filed 26 February 2026
Study design
Company filing
Funding
not stated in the source

A company description. PubChem returned no record for ACCG-2671 or ACCG2671 on 10 October 2026, and the sources give no INN; those findings come from record searches, not from this filing.

Read the original source
Company statement in the 10-K: receptor potency and oral weight loss in diet-induced obese rats

Animal study

Structure Therapeutics Form 10-K for 2025, filed 26 February 2026. SEC EDGAR.

ACCG-2671 showed high binding affinity and balanced potency in human calcitonin receptor and amylin receptor functional assays, and sub-nanomolar potency in the company's DACRA assay. In diet-induced obese rats, oral doses produced significant dose-dependent body weight reductions, and combination with semaglutide (concurrent or as an add-on) gave more weight loss than ACCG-2671 alone. The filing's own heading says "cagrilintide-like efficacy" in the rat model.

Participants / model
Diet-induced obese rats and cell assays with human receptors
Treatment
Oral dosing in rats; dose not stated in the sources reviewed
Follow-up
not stated in the source
Study design
Company statement of preclinical results in a filing; no peer-reviewed paper found
Funding
not stated in the source

The "cagrilintide-like efficacy" heading is the company's own comparison in the rat model, not a human result. No peer-reviewed preclinical paper was found.

Read the original source
Company statement, 8 September 2026: 31 healthy adults, half-life about 6 days, not peer reviewed

Clinical trial

Structure Therapeutics Form 8-K exhibit dated 8 September 2026. SEC EDGAR.

31 healthy adults without obesity received a single dose of 1, 2, 5 or 10 mg or placebo. Tmax was 1 to 1.5 hours, exposure was dose proportional, and the terminal half-life was about 6 days. There were no serious adverse events, no drug-related adverse events leading to discontinuation and no events of drug-induced liver injury. No nausea or vomiting was reported on placebo, 1 mg or 2 mg. Gastrointestinal events emerged at 5 mg (nausea in 4 of 5, vomiting in 3 of 5) and at 10 mg (6 of 6 participants; the release does not say which events). Exploratory findings: a single 10 mg dose (n = 6) was associated with a mean body weight reduction of 3.3% at day 24, and the bone resorption marker CTX-1 fell by about 60% on day 2 across the active cohorts. The release names ACCG-2671 and the GLP-1 agonist aleniglipron as the company's two lead product candidates, repeats the description "oral, non-peptide, small molecule" DACRA, and says the 84-day multiple dose part has started in five cohorts of people with obesity, with topline data expected in the first half of 2027.

Participants / model
Healthy adults without obesity, 31 in the single ascending dose part
Treatment
Single oral dose, 1 to 10 mg
Follow-up
Body weight at day 24; CTX-1 on day 2
Study design
Company statement of phase 1/2a single ascending dose topline results; not peer reviewed
Funding
not stated in the source

The release gives no placebo comparison for the weight figure, and the participants did not have obesity. The 10 mg gastrointestinal events were not itemized. The release calls the program both phase 1/2a and phase 1b/2a.

Read the original source

What risks did the single-dose study report?

The company reported no serious adverse events, no drug-related discontinuations and no drug-induced liver injury. Gastrointestinal events appeared in most participants at higher doses: nausea in 4 of 5 and vomiting in 3 of 5 at 5 mg, and events in 6 of 6 at 10 mg.

In the company-reported single ascending dose study of 31 healthy adults without obesity, there were no serious adverse events, no drug-related adverse events leading to discontinuation and no events of drug-induced liver injury. No nausea or vomiting was reported on placebo, 1 mg or 2 mg. Gastrointestinal events emerged at 5 mg (nausea in 4 of 5, vomiting in 3 of 5) and at 10 mg (6 of 6 participants).

The release does not say which events occurred at 10 mg. Multiple-dose safety data are not expected until the first half of 2027, and no peer-reviewed safety report exists.

Company statement, 8 September 2026: 31 healthy adults, half-life about 6 days, not peer reviewed

Clinical trial

Structure Therapeutics Form 8-K exhibit dated 8 September 2026. SEC EDGAR.

31 healthy adults without obesity received a single dose of 1, 2, 5 or 10 mg or placebo. Tmax was 1 to 1.5 hours, exposure was dose proportional, and the terminal half-life was about 6 days. There were no serious adverse events, no drug-related adverse events leading to discontinuation and no events of drug-induced liver injury. No nausea or vomiting was reported on placebo, 1 mg or 2 mg. Gastrointestinal events emerged at 5 mg (nausea in 4 of 5, vomiting in 3 of 5) and at 10 mg (6 of 6 participants; the release does not say which events). Exploratory findings: a single 10 mg dose (n = 6) was associated with a mean body weight reduction of 3.3% at day 24, and the bone resorption marker CTX-1 fell by about 60% on day 2 across the active cohorts. The release names ACCG-2671 and the GLP-1 agonist aleniglipron as the company's two lead product candidates, repeats the description "oral, non-peptide, small molecule" DACRA, and says the 84-day multiple dose part has started in five cohorts of people with obesity, with topline data expected in the first half of 2027.

Participants / model
Healthy adults without obesity, 31 in the single ascending dose part
Treatment
Single oral dose, 1 to 10 mg
Follow-up
Body weight at day 24; CTX-1 on day 2
Study design
Company statement of phase 1/2a single ascending dose topline results; not peer reviewed
Funding
not stated in the source

The release gives no placebo comparison for the weight figure, and the participants did not have obesity. The 10 mg gastrointestinal events were not itemized. The release calls the program both phase 1/2a and phase 1b/2a.

Read the original source
Registry: phase 1/2 first-in-human, 164 planned, no posted results

Trial registry record

ClinicalTrials.gov. NCT07815678 (sponsor Aconcagua Bio, Inc.).

The registry lists the sponsor of the ACCG-2671 first-in-human study as "Aconcagua Bio, Inc., a wholly owned subsidiary of Structure Therapeutics". NCT07815678 is a randomized, triple-masked phase 1/2 study of safety, tolerability, pharmacokinetics and food effect, estimated 164 participants aged 25 to 75, with a listed start of 29 December 2025, primary completion in March 2027, and first posted on 11 September 2026 (after the listed start). Parts 1 and 2 enroll healthy participants, and part 3 enrolls otherwise healthy participants with obesity, with safety, vital sign, ECG and laboratory primary outcomes. The registry has no posted results.

Participants / model
Healthy adults, then adults with obesity (planned)
Treatment
Oral, single and multiple ascending doses
Follow-up
Listed start 29 December 2025; primary completion March 2027
Study design
Official trial registry
Funding
not stated in the source

A registration, not an outcome. The registry was first posted more than eight months after the listed start date.

Read the original source

Why does ACCG-2671 sit in C tier?

The only human data are single-dose company results in 31 healthy adults without obesity, with no peer-reviewed report. The 3.3% weight change came from 6 participants with no placebo comparison, and gastrointestinal events appeared in most participants at 5 and 10 mg.

The C reflects single-dose results in 31 healthy adults without obesity, announced by the company in an SEC exhibit, with no peer-reviewed report. The amylin mechanism has support from class data from injectable amylin analogs, such as the published phase 2 trial of petrelintide on its own page, and a 6-day half-life by mouth is notable.

Against that, the 3.3% weight change came from 6 participants with no placebo comparison, gastrointestinal events appeared in most participants at 5 and 10 mg, and multiple-dose data are not expected until the first half of 2027. The data are thin, which fits C.

Company statement, 8 September 2026: 31 healthy adults, half-life about 6 days, not peer reviewed

Clinical trial

Structure Therapeutics Form 8-K exhibit dated 8 September 2026. SEC EDGAR.

31 healthy adults without obesity received a single dose of 1, 2, 5 or 10 mg or placebo. Tmax was 1 to 1.5 hours, exposure was dose proportional, and the terminal half-life was about 6 days. There were no serious adverse events, no drug-related adverse events leading to discontinuation and no events of drug-induced liver injury. No nausea or vomiting was reported on placebo, 1 mg or 2 mg. Gastrointestinal events emerged at 5 mg (nausea in 4 of 5, vomiting in 3 of 5) and at 10 mg (6 of 6 participants; the release does not say which events). Exploratory findings: a single 10 mg dose (n = 6) was associated with a mean body weight reduction of 3.3% at day 24, and the bone resorption marker CTX-1 fell by about 60% on day 2 across the active cohorts. The release names ACCG-2671 and the GLP-1 agonist aleniglipron as the company's two lead product candidates, repeats the description "oral, non-peptide, small molecule" DACRA, and says the 84-day multiple dose part has started in five cohorts of people with obesity, with topline data expected in the first half of 2027.

Participants / model
Healthy adults without obesity, 31 in the single ascending dose part
Treatment
Single oral dose, 1 to 10 mg
Follow-up
Body weight at day 24; CTX-1 on day 2
Study design
Company statement of phase 1/2a single ascending dose topline results; not peer reviewed
Funding
not stated in the source

The release gives no placebo comparison for the weight figure, and the participants did not have obesity. The 10 mg gastrointestinal events were not itemized. The release calls the program both phase 1/2a and phase 1b/2a.

Read the original source
PubMed search, 10 October 2026: no record for ACCG-2671

PubMed search record

PubMed searches run on 10 October 2026 for ACCG-2671 and ACCG2671 (0 records each), a free-text query for Structure Therapeutics oral small molecule amylin receptor agonist (2 records) and an affiliation query for Structure Therapeutics with amylin or aleniglipron (2 records).

PubMed queries for ACCG-2671 and ACCG2671 returned 0 records each. A free-text query for Structure Therapeutics oral small molecule amylin receptor agonist returned 2 incretin review papers whose abstracts do not mention ACCG, and an affiliation query for Structure Therapeutics with amylin or aleniglipron returned 2 records about the GLP-1 agonist aleniglipron (a phase 2b report and its correction). No peer-reviewed report of ACCG-2671 data was found.

Participants / model
Records returned, not a population
Treatment
Not applicable
Follow-up
Searches run on 10 October 2026
Study design
Literature search
Funding
not stated in the source

A search result shows what PubMed returned on that date. It is not proof that no unindexed study exists.

Read the original source
Registry: phase 1/2 first-in-human, 164 planned, no posted results

Trial registry record

ClinicalTrials.gov. NCT07815678 (sponsor Aconcagua Bio, Inc.).

The registry lists the sponsor of the ACCG-2671 first-in-human study as "Aconcagua Bio, Inc., a wholly owned subsidiary of Structure Therapeutics". NCT07815678 is a randomized, triple-masked phase 1/2 study of safety, tolerability, pharmacokinetics and food effect, estimated 164 participants aged 25 to 75, with a listed start of 29 December 2025, primary completion in March 2027, and first posted on 11 September 2026 (after the listed start). Parts 1 and 2 enroll healthy participants, and part 3 enrolls otherwise healthy participants with obesity, with safety, vital sign, ECG and laboratory primary outcomes. The registry has no posted results.

Participants / model
Healthy adults, then adults with obesity (planned)
Treatment
Oral, single and multiple ascending doses
Follow-up
Listed start 29 December 2025; primary completion March 2027
Study design
Official trial registry
Funding
not stated in the source

A registration, not an outcome. The registry was first posted more than eight months after the listed start date.

Read the original source

Studies and sources

Structure Therapeutics 10-K (filed 26 February 2026): oral small-molecule DACRA

Regulatory record

Structure Therapeutics Form 10-K for 2025, filed 26 February 2026. SEC EDGAR.

The 10-K says the company announced the selection of ACCG-2671 as its lead oral amylin agonist for obesity in December 2024, designed as an oral small molecule dual amylin and calcitonin receptor agonist (DACRA), and that a Phase 1 study began in December 2025. It calls ACCG-2671 its lead oral amylin candidate. A second candidate, ACCG-3535, is described as a different chemical structure.

Participants / model
Company description, not a clinical population
Treatment
Oral small molecule
Follow-up
Filed 26 February 2026
Study design
Company filing
Funding
not stated in the source

A company description. PubChem returned no record for ACCG-2671 or ACCG2671 on 10 October 2026, and the sources give no INN; those findings come from record searches, not from this filing.

Read the original source
Company statement in the 10-K: receptor potency and oral weight loss in diet-induced obese rats

Animal study

Structure Therapeutics Form 10-K for 2025, filed 26 February 2026. SEC EDGAR.

ACCG-2671 showed high binding affinity and balanced potency in human calcitonin receptor and amylin receptor functional assays, and sub-nanomolar potency in the company's DACRA assay. In diet-induced obese rats, oral doses produced significant dose-dependent body weight reductions, and combination with semaglutide (concurrent or as an add-on) gave more weight loss than ACCG-2671 alone. The filing's own heading says "cagrilintide-like efficacy" in the rat model.

Participants / model
Diet-induced obese rats and cell assays with human receptors
Treatment
Oral dosing in rats; dose not stated in the sources reviewed
Follow-up
not stated in the source
Study design
Company statement of preclinical results in a filing; no peer-reviewed paper found
Funding
not stated in the source

The "cagrilintide-like efficacy" heading is the company's own comparison in the rat model, not a human result. No peer-reviewed preclinical paper was found.

Read the original source
Registry: phase 1/2 first-in-human, 164 planned, no posted results

Trial registry record

ClinicalTrials.gov. NCT07815678 (sponsor Aconcagua Bio, Inc.).

The registry lists the sponsor of the ACCG-2671 first-in-human study as "Aconcagua Bio, Inc., a wholly owned subsidiary of Structure Therapeutics". NCT07815678 is a randomized, triple-masked phase 1/2 study of safety, tolerability, pharmacokinetics and food effect, estimated 164 participants aged 25 to 75, with a listed start of 29 December 2025, primary completion in March 2027, and first posted on 11 September 2026 (after the listed start). Parts 1 and 2 enroll healthy participants, and part 3 enrolls otherwise healthy participants with obesity, with safety, vital sign, ECG and laboratory primary outcomes. The registry has no posted results.

Participants / model
Healthy adults, then adults with obesity (planned)
Treatment
Oral, single and multiple ascending doses
Follow-up
Listed start 29 December 2025; primary completion March 2027
Study design
Official trial registry
Funding
not stated in the source

A registration, not an outcome. The registry was first posted more than eight months after the listed start date.

Read the original source
Company statement, 8 September 2026: 31 healthy adults, half-life about 6 days, not peer reviewed

Clinical trial

Structure Therapeutics Form 8-K exhibit dated 8 September 2026. SEC EDGAR.

31 healthy adults without obesity received a single dose of 1, 2, 5 or 10 mg or placebo. Tmax was 1 to 1.5 hours, exposure was dose proportional, and the terminal half-life was about 6 days. There were no serious adverse events, no drug-related adverse events leading to discontinuation and no events of drug-induced liver injury. No nausea or vomiting was reported on placebo, 1 mg or 2 mg. Gastrointestinal events emerged at 5 mg (nausea in 4 of 5, vomiting in 3 of 5) and at 10 mg (6 of 6 participants; the release does not say which events). Exploratory findings: a single 10 mg dose (n = 6) was associated with a mean body weight reduction of 3.3% at day 24, and the bone resorption marker CTX-1 fell by about 60% on day 2 across the active cohorts. The release names ACCG-2671 and the GLP-1 agonist aleniglipron as the company's two lead product candidates, repeats the description "oral, non-peptide, small molecule" DACRA, and says the 84-day multiple dose part has started in five cohorts of people with obesity, with topline data expected in the first half of 2027.

Participants / model
Healthy adults without obesity, 31 in the single ascending dose part
Treatment
Single oral dose, 1 to 10 mg
Follow-up
Body weight at day 24; CTX-1 on day 2
Study design
Company statement of phase 1/2a single ascending dose topline results; not peer reviewed
Funding
not stated in the source

The release gives no placebo comparison for the weight figure, and the participants did not have obesity. The 10 mg gastrointestinal events were not itemized. The release calls the program both phase 1/2a and phase 1b/2a.

Read the original source
PubMed search, 10 October 2026: no record for ACCG-2671

PubMed search record

PubMed searches run on 10 October 2026 for ACCG-2671 and ACCG2671 (0 records each), a free-text query for Structure Therapeutics oral small molecule amylin receptor agonist (2 records) and an affiliation query for Structure Therapeutics with amylin or aleniglipron (2 records).

PubMed queries for ACCG-2671 and ACCG2671 returned 0 records each. A free-text query for Structure Therapeutics oral small molecule amylin receptor agonist returned 2 incretin review papers whose abstracts do not mention ACCG, and an affiliation query for Structure Therapeutics with amylin or aleniglipron returned 2 records about the GLP-1 agonist aleniglipron (a phase 2b report and its correction). No peer-reviewed report of ACCG-2671 data was found.

Participants / model
Records returned, not a population
Treatment
Not applicable
Follow-up
Searches run on 10 October 2026
Study design
Literature search
Funding
not stated in the source

A search result shows what PubMed returned on that date. It is not proof that no unindexed study exists.

Read the original source
FDA record search, 10 October 2026: no application or label

Regulatory record

U.S. Food and Drug Administration, openFDA Drugs@FDA query and DailyMed drug name search for ACCG-2671, run on 10 October 2026.

An openFDA Drugs@FDA query for ACCG-2671 returned "No matches found" (a control query for semaglutide returned records), and a DailyMed drug name search for ACCG-2671 returned 0 labels.

Participants / model
FDA databases, not a clinical population
Treatment
Name search
Follow-up
Queries run on 10 October 2026
Study design
Dated US approval-record search
Funding
not stated in the source

A search result shows what the databases returned on that date. It is US-scoped and does not cover approvals elsewhere.

Read the original source

Why is ACCG-2671 in C tier?

C fits a compound whose only human data are single-dose company results in 31 healthy adults without obesity, with no peer-reviewed report. The amylin mechanism has class support and a 6-day half-life by mouth is notable, but the 3.3% weight change came from 6 participants with no placebo comparison, gastrointestinal events appeared in most participants at 5 and 10 mg, and multiple-dose data are not expected until the first half of 2027.